SEATTLE, WA--(Marketwired - Jun 20, 2013) - Atossa Genetics, Inc. (
Atossa's MASCT system is used by physicians and nurses to collect a small amount of nipple aspirate fluid for cytological and genomic analysis at Atossa's wholly-owned National Reference Laboratory for Breast Health .
Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "Fisher HealthCare is a recognized leader in providing diagnostic solutions to customers in the acute care, physician office and reference lab markets and we are excited to have entered into this distribution agreement. We believe our ForeCYTE test represents a significant breakthrough in breast cancer risk assessment and we look forward to working with our partners to make the ForeCYTE test a standard of care."
Mark Zacur, Vice President of Marketing & Business Development for Fisher HealthCare, stated, "We are pleased to partner with Atossa Genetics to help make the ForeCYTE test available to women across the U.S. We believe that the ForeCYTE test has the potential to have a meaningful impact on improving women's breast health."
Just as the Pap smear has reduced cervical cancer rates by more than 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection and treatment of the precursor changes that lead to breast cancer.
About the ForeCYTE Breast Health Risk Assessment Test
The ForeCYTE test, the "Pap smear" for breast cancer, is a painless, quick and non-invasive procedure performed in a physician's office. The test provides vital early detection of pre-cancerous conditions that may progress to cancer over an approximately eight-year period before cancer can be detected by mammography or other means. The ForeCYTE test is intended for the 110 million women in the U.S. ages 18-73, including younger women, women with dense breasts , breast implants and BRCA gene mutations. Please click here for a video of the ForeCYTE test: http://vimeo.com/62365818 .
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA.
For additional information, please visit www.atossagenetics.com .
Atossa Genetics Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Contact: Atossa Genetics, Inc. Kyle Guse CFO & General Counsel (O) 800-351-3902 Email Contact Matthew D. Haines (Investors) Managing Director MBS Value Partners (O) 212-710-9686 Email Contact
